Vicarious Surgical Hits Key Milestone on Path to Reinvent Hernia Repair

WALTHAM, MA – March 30, 2026 – In a significant step toward reshaping the future of minimally invasive surgery, Vicarious Surgical announced today the successful completion of integrated benchtop testing for its full suite of surgical instruments. The milestone, focused on the company's first targeted procedure of ventral hernia repair, validates core components of its technology and marks a critical de-risking event on its ambitious path to market.

The Waltham-based company confirmed that its three primary instruments—needle drivers, fenestrated graspers, and monopolar scissors—performed successfully in a unified system evaluation. This achievement provides crucial evidence that the components of its novel single-port robot can work in concert, moving the technology closer to planned preclinical studies and an eventual design freeze.

"This milestone represents an important step in systematically de-risking our system as we advance toward design freeze and first-in-human use," said Stephen From, Chief Executive Officer of Vicarious Surgical. "Demonstrating reliable, integrated performance across our full instrument suite, including stability under electrosurgical energy, reinforces our confidence in the system architecture and our development timeline. Each successful test brings us closer to enabling a new standard in minimally invasive robotic surgery."

A Technological Leap in a Crowded Field

Vicarious Surgical aims to differentiate itself in a surgical robotics market dominated by giants like Intuitive Surgical and its da Vinci system, as well as growing competition from titans like Medtronic and Johnson & Johnson. The company’s strategy hinges on a unique technological approach designed to be more efficient, less invasive, and potentially more cost-effective.

Unlike traditional multi-port robotic systems that require several incisions, the Vicarious Surgical System is designed to operate through a single 1.2-centimeter incision. From this single port, the system deploys two “human-like” robotic arms and a camera, designed to replicate the full motion of a surgeon's hands and wrists. The company's vision is to virtually transport the surgeon inside the patient's abdomen with immersive 3D visualization and unparalleled dexterity.

The recent benchtop test was particularly notable for the performance of the monopolar scissors. These instruments, used for cutting and cauterizing tissue, successfully demonstrated mechanical cutting capabilities while under electrical load. Crucially, the system’s camera and motion sensors remained stable, with no degradation in performance—a key validation that the robot can function effectively in a simulated, clinically relevant surgical environment where electrosurgical energy is a constant.

The High-Stakes Path from Benchtop to Bedside

While this technical achievement is significant, it represents one step on a long and financially demanding journey. As a pre-revenue company, Vicarious Surgical operates in a high-risk, high-reward environment. The company has been transparent about its financial challenges, including a strategic focus on reducing its cash burn. After reporting a net loss of $50.2 million for 2025—an improvement over the prior year—the company is targeting a much leaner cash burn of approximately $19 million for 2026 through cost-control measures and workforce reductions.

These financial pressures were highlighted by the company's recent delisting from the New York Stock Exchange in March 2026, after failing to meet minimum market capitalization requirements. The company’s stock now trades on the OTCQB Venture Market, a move it describes as a strategic step toward a potential future listing on the Nasdaq Capital Market. This path underscores the immense capital required to bring a revolutionary medical device from concept to commercialization.

Despite the financial hurdles, the company’s progress continues to draw attention. Its technology is backed by prominent investors, including Bill Gates, and its focus on a specific, high-volume procedure like ventral hernia repair is a calculated strategy to gain a foothold in the competitive robotics space.

Navigating the Regulatory Gauntlet

The road to any operating room runs directly through the U.S. Food and Drug Administration (FDA), a rigorous and lengthy process for any novel medical device. However, Vicarious Surgical holds a key advantage: its system was the first full surgical robotic system to receive a Breakthrough Device Designation from the FDA. This designation is reserved for technologies that could provide more effective treatment for life-threatening or irreversibly debilitating conditions. While it does not guarantee approval, it is intended to expedite the development and review process, providing more frequent and collaborative interaction with the FDA.

With the successful benchtop testing complete, Vicarious Surgical is now preparing to advance to the next critical phase of preclinical validation. This will involve studies on both cadavers and pigs to further test the system's safety and efficacy in a more realistic anatomical setting. These studies are essential for gathering the data needed to finalize the system's design, a milestone the company is targeting by the end of 2026 before moving toward human clinical trials and an eventual submission for FDA clearance.

Reimagining Recovery for Hernia Patients

Beyond the technical, financial, and regulatory battles, the ultimate goal of the Vicarious Surgical System is to transform the experience for both surgeons and patients. Ventral hernia repair is a common and often complex procedure. Traditional open surgery can require a large incision, leading to significant post-operative pain, long recovery times, and a higher risk of complications. While existing multi-port laparoscopic and robotic approaches have improved outcomes, they still require multiple incisions.

The potential for a single, small incision promises a significant leap forward. For patients, this could mean less pain, reduced scarring, shorter hospital stays, and a faster return to normal activities. For surgeons, the system's enhanced dexterity and immersive visualization aim to make complex procedures simpler and more precise. For the broader healthcare system, these improvements could translate into lower overall costs through increased operating room efficiency and reduced post-operative care.

As Vicarious Surgical moves from the lab bench toward the operating table, this latest milestone is a promising signal. The journey is far from over, but the successful integration of its core instruments shows that the ambitious vision of a new standard in minimally invasive surgery is one step closer to becoming a clinical reality.